Lucid Diagnostics (LUCD) announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state. The new policy will cover Lucid’s EsoGuard Esophageal DNA Test in patients who meet established criteria for esophageal precancer testing consistent with professional society guidelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Raises $15.3 Million in Stock Offering
- Lucid Diagnostics Announces $15.3 Million Direct Offering
- Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering
- Lucid announces investigators awarded $8M grant to investigate EsoCheck
- Lucid Diagnostics regains Nasdaq compliance
Questions or Comments about the article? Write to editor@tipranks.com